ID: ALA5291268

Max Phase: Preclinical

Molecular Formula: C16H19ClN4O2

Molecular Weight: 334.81

Representations

Canonical SMILES:  CNc1cc(Oc2cccc(NC(=O)C(C)(C)CCl)c2)ncn1

Standard InChI:  InChI=1S/C16H19ClN4O2/c1-16(2,9-17)15(22)21-11-5-4-6-12(7-11)23-14-8-13(18-3)19-10-20-14/h4-8,10H,9H2,1-3H3,(H,21,22)(H,18,19,20)

Standard InChI Key:  MCCRYXNDYLEZBK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 334.81

Molecular Weight (Monoisotopic): 334.1197

AlogP: 3.51

#Rotatable Bonds: 6

Polar Surface Area: 76.14

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.42

CX Basic pKa: 4.78

CX LogP: 3.32

CX LogD: 3.32

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.79

Np Likeness Score: -1.48

References

1. Kim DR, Orr MJ, Kwong AJ, Deibler KK, Munshi HH, Bridges CS, Chen TJ, Zhang X, Lacorazza HD, Scheidt KA..  (2023)  Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.,  14  (5): [PMID:37197477] [10.1021/acsmedchemlett.3c00029]

Source

Source(1):

• Scientific Literature